PCM
RLMD icon

Parsons Capital Management’s Relmada Therapeutics RLMD Stock Holding History

Parsons Capital Management’s Portfolio RLMD Stock Details RLMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.45M Buy
354,069
+1,569
+0.4% +$11K 0.11% 178
2026
Q1 		$2.45M Buy
352,500
+89,500
+34% +$423K 0.11% 169
2025
Q4 		$1.27M Buy
263,000
+99,664
+61% +$334K 0.07% 217
2025
Q3 		$328K Hold
163,336
– – 0.02% 371
2025
Q2 		$98.1K Hold
163,336
– – 0.01% 436
2025
Q1 		$44.1K Hold
163,336
– – ﹤0.01% 430
2024
Q4 		$84.9K Sell
163,336
-839,359
-84% -$2.05M ﹤0.01% 435
2024
Q3 		$3.25M Buy
1,002,695
+26,750
+3% +$86.6K 0.21% 112
2024
Q2 		$2.93M Buy
975,945
+2,425
+0.2% +$8.77K 0.2% 114
2024
Q1 		$4.53M Buy
973,520
+23,679
+2% +$114K 0.31% 77
2023
Q4 		$3.93M Sell
949,841
-24,241
-2% -$71.8K 0.28% 85
2023
Q3 		$2.92M Buy
974,082
+100,770
+12% +$299K 0.23% 93
2023
Q2 		$2.15M Buy
873,312
+151,146
+21% +$418K 0.16% 127
2023
Q1 		$1.63M Buy
722,166
+225,912
+46% +$779K 0.13% 158
2022
Q4 		$1.73M Sell
496,254
-7,547
-1% -$66.3K 0.14% 143
2022
Q3 		$18.7M Buy
503,801
+25
+0% +$693 1.67% 9
2022
Q2 		$9.57M Buy
503,776
+700
+0.1% +$15.3K 0.86% 21
2022
Q1 		$13.6M Sell
503,076
-336
-0.1% -$6.95K 1.03% 17
2021
Q4 		$11.3M Buy
503,412
+30,438
+6% +$677K 0.81% 22
2021
Q3 		$12.4M Buy
472,974
+22,562
+5% +$604K 0.97% 18
2021
Q2 		$14.4M Sell
450,412
-1,000
-0.2% -$34.7K 1.1% 12
2021
Q1 		$15.9M Sell
451,412
-200
-0% -$7K 1.3% 10
2020
Q4 		$14.5M Sell
451,612
-3,525
-0.8% -$121K 1.25% 11
2020
Q3 		$17.1M Buy
455,137
+1,050
+0.2% +$40.6K 1.67% 7
2020
Q2 		$20.3M Buy
454,087
+28,512
+7% +$1.21M 2.16% 6
2020
Q1 		$14.5M Buy
425,575
+58,642
+16% +$2.36M 1.87% 7
2019
Q4 		$14.3M Buy
+366,933
New +$11.1M 1.44% 11

Other funds holding RLMD

JT
Jupiter Topco New York $245B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $322M AUM
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
SSC
Spruce Street Capital New York $510M AUM
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JHC
Jones Hill Capital New York $470M AUM
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Parsons Capital Management's RLMD Position: Q2 2026 in Review

Parsons Capital Management increased its Relmada Therapeutics (RLMD) stake by 0.45% in Q2 2026, buying an estimated $11K and bringing the position to 354,069 shares worth $2.45M. The position accounts for 0.11% of the portfolio, ranked #178.

Parsons Capital Management first reported a position in RLMD in Q4 2019 and has held it in 27 quarters since. The position peaked at $20.3M in Q2 2020. 126 funds tracked by Wall St. Rank hold RLMD as of Q2 2026.

  • Parsons Capital Management held 354,069 shares of Relmada Therapeutics worth $2.45M as of Q2 2026.
  • Parsons Capital Management bought 1,569 Relmada Therapeutics shares in Q2 2026, an estimated $11K.
  • Relmada Therapeutics made up 0.11% of Parsons Capital Management's portfolio in Q2 2026, its #178 holding.
  • Parsons Capital Management first reported a position in Relmada Therapeutics in Q4 2019 and has held it in 27 quarters since.
  • Parsons Capital Management's Relmada Therapeutics position peaked at $20.3M in Q2 2020.
  • 126 funds tracked by Wall St. Rank held Relmada Therapeutics as of Q2 2026.

Based on Parsons Capital Management's 13F filing for Q2 2026, filed 24 Jul 2026.